Introduction

Chlamydia
Chlamydia has been nationally notifiable since 1991. It is a genital infection caused by the bacterium Chlamydia trachomatis and is the most commonly reported sexually transmitted infection (STI) in Canada. Infections are often asymptomatic in both males and females. In the absence of screening, these infections remain undiagnosed and contribute to the spread of chlamydia in sexually active individuals (1) . A common complication associated with untreated and recurring chlamydia in females is pelvic inflammatory disease, which can lead to chronic pelvic pain, ectopic pregnancy and infertility. In males, complications are rarer but include epididymo-orchitis and infertility. Untreated chlamydia in pregnant women can be transmitted to their newborns, causing neonatal conjunctivitis or pneumonia. As with other STIs, chlamydia increases infection with and transmission of the human immunodeficiency virus (HIV). It recruits target cells for HIV to the genital tract and increases the shedding of HIVinfected cells (2, 3) .
Between 1991 and 1997, the rate of reported cases of chlamydia decreased steadily among both males and females, after which rates began to rise (4) .
Lymphogranuloma venereum
Lymphogranuloma venereum (LGV) is an STI caused by C. trachomatis serovars L1, L2 and L3. Infections caused by these serovars preferentially invade lymph tissue and tend to be more invasive than those caused by non-LGV chlamydia. Signs and symptoms include painful, ulcerative proctitis, with inguinal and/or femoral lymphadenopathy or buboes, accompanied by fever, myalgia and arthralgia. Untreated LGV infection can result in severe complications including destruction of rectal and genital tissue. Although uncommon, in some cases, meningoencephalitis, hepatitis and death can also occur.
LGV is endemic in parts of Africa, Asia, South America and the Caribbean region and was relatively uncommon in Canada until 2003 (5) . At that time, outbreaks of LGV began occurring among men who have sex with men in urban centres in Canada (6) . Outbreaks among MSM have also been reported in European countries and the United States (7, 8, 9, 10) . Recent data suggest that the infection has become endemic in the MSM population in some of these countries (11) . In response to the emergence of LGV in Europe, Canada 
Methods
Data collection
Data on laboratory-confirmed chlamydia cases were reported to the Canadian Notifiable Disease Surveillance System (CNDSS) by provincial and territorial health authorities according to the Agency's Case Definitions for Communicable Diseases under National Surveillance (14) (see box below). Data are submitted in a variety of formats (e.g., line-listed electronic, paper-based case reports, or aggregate data) and are verified and loaded into the CNDSS database by Agency personnel.
Confirmatory testing for suspected LGV cases is performed by the National Microbiology Laboratory (NML) by nucleic acid amplification testing (NAAT) and data on these cases are then shared with the Centre for Communicable Disease and Infection Control (CCDIC). Diagnosis of probable cases is based on serological testing alone and is done at provincial laboratories. Where possible, provincial/territorial health authorities use a standardized national case report form to collect enhanced epidemiological data on confirmed and probable cases and submit the data directly to CCDIC. At the current time, it is not possible to link case report forms on confirmed cases submitted to CCDIC with their corresponding NML data.
Data analysis
Chlamydia data extracted from the CNDSS were analyzed by CCDIC staff. Rates were calculated by age group and sex using population estimates obtained from the Statistics Canada Demography Division. Rate change calculations were made on unrounded figures for greater precision.
Counts of LGV cases reported by the NML and by provincial/territorial health authorities are included separately, as there is currently no method of linking these two data sources. Confirmed cases reported by the NML may duplicate confirmed cases also reported by the provinces, but this degree of overlap is difficult to quantify.
Surveillance is considered to be within the mandate of F/P/T programs and does not constitute human research; therefore, no research ethics board approval was sought.
Results
Chlamydia
In 2012, 103,716 cases of chlamydia were reported, corresponding to a rate of 298.7 per 100,000. The 2012 rate was a 57.6% increase from the rate of 189.6 per 100,000 in 2003. Among males, rates increased by 74.8%, from 121.3 to 212.0 per 100,000; among females, rates increased by 49.5%, from 256.5 to 383.5 per 100,000 ( Figure  1 ). In 2012, rates were almost twice as high among females as compared to males and the majority (80.2%) of reported chlamydia infections occurred in persons under 30 years (Figure 2 ). In 2012, the highest rates were in the age 20 to 24 age group, though rates in females were twice as high as in males of this age (2151.7 per 100,000 vs. 1073.9 per 100,000, respectively). Among older age groups, the gap between sexes was less pronounced and even reversed; in 2012, the rates of reported cases were higher among men than women in those aged 40 and older (Figure 2 ).
Between 2003 and 2012, rates of reported cases of chlamydia increased steadily among both males and females aged 10 and above. The highest relative rate increase occurred among those aged 10 to 14 (167.0%) while the highest relative rate increase in females occurred among those aged 60 and over (266.8%) (data not shown). 
Lymphogranuloma venereum
As of December 2012, 170 cases were reported to the Agency by provincial health authorities (including 104 confirmed and 66 probable cases) ( Table 1 ). All confirmed cases were male and predominantly MSM. In 2012 alone, there were eight confirmed and four probable cases reported by the provinces and territories, however, there were 38 laboratory-confirmed cases reported by the NML. 
Discussion
Increases in the rates of reported cases of chlamydia have been observed in Canada over the last decade. There are several factors that must be taken into account when considering these data.
The introduction of more sensitive nucleic acid amplification testing (NAAT) in the mid-1990s undoubtedly led to an increase in the number of chlamydia cases detected. NAAT allows urine specimens to be used rather than swabs, which are easier to collect and more acceptable to patients. As a result, the number of people, particularly males, who go for testing has likely increased as well. More effective screening and contact tracing may have a similar effect (15, 16) . A recent estimation of chlamydia disease burden in Canada found that observed increases in chlamydia prevalence could be explained by effective case finding and expansion of screening programs (17).
Over time, the rate of reported cases of chlamydia has consistently been approximately twice as high in females as in males; however, this disparity is much more pronounced in younger age groups. Younger women are biologically more susceptible to chlamydial infection (18, 19). In addition, women are more likely to be screened for STIs (20, 21). 
Introduction
Gonorrhea has been nationally notifiable since 1924 and is the second most commonly reported sexuallytransmitted infection (STI) in Canada. Gonorrhea is a genital bacterial infection caused by Neisseria gonorrhoeae and if left untreated, can lead to complications for both sexes. There can be severe consequences for females, including pelvic inflammatory disease, which often leads to chronic abdominal pain, infertility and ectopic pregnancy. In males, untreated infections can result in epididymitis and rare cases of infertility. An uncommon complication of gonorrhea is the spread of infection to the blood stream and joints (1) . Like other STIs, gonorrhea increases the risk of HIV acquisition and transmission, possibly by increasing the concentration of HIV target cells in genital secretions and viral shedding (2).
Between 1991 and 1997, Canada experienced a sharp decline in the rates of reported cases of gonorrhea and rates were similar between males and females. After 1997, rates began to rise (3). 
Methods
Data collection
Data on laboratory-confirmed gonorrhea cases were reported to the Canadian Notifiable Disease Surveillance System (CNDSS) by provincial and territorial health authorities according to the Agency's Case Definitions for Communicable Diseases under National Surveillance (5) (see box below). Data are submitted in a variety of formats (e.g., line-listed electronic, paper-based case reports, or aggregate data) and are verified and loaded into the CNDSS database by Agency personnel.
Case definitions of confirmed case of gonorrhea
Laboratory-evidence of infection in genitourinary or extra-genital specimens:
 Detection of Neisseria gonorrhoeae by culture, OR  Detection of N. gonorrhoeae nucleic acid.
Data analysis
Gonorrhea data extracted from the CNDSS were analyzed by Centre for Communicable Diseases and Infection Control (CCDIC) staff. Rates were calculated by age group and sex using population estimates obtained from the Statistics Canada Demography Division. Rate change calculations were made on unrounded figures for greater precision. Surveillance is considered to be within the mandate of Federal/Provincial/Territorial (F/P/T) programs and does not constitute human research; therefore, no research ethics board approval was sought.
Results
In 2012, 12,561 cases of gonorrhea were reported through the CNDSS, corresponding to a rate of 36.2 per 100,000. The 2012 rate was a 38.9% increase from the rate of 26.0 per 100,000 in 2003. Over this ten-year time frame, rates increased among both males and females; males experienced a 29.1% relative rate increase while females experienced a 53.9% relative rate increase. Around 2006, rates of reported cases of gonorrhea began to show signs of stabilizing, with minor fluctuations from year to year. (Figure 1 ).
Figure 1: Overall and sex-specific rates of gonorrhea, 2003 to 2012, Canada
Rates of reported cases of gonorrhea in 2012 were higher among females than males in those less than 25 years of age; but were higher in males than females among those aged 25 years and over (Figure 2 ). The highest rates of gonorrhea were observed among males and females aged 20 to 24.
Between 2003 and 2012, rates of reported cases of gonorrhea increased among both males and females aged 10 and above. The greatest relative rate increase observed among males was in those aged 10 to 14 years (262.0%), from 0.5 to 1.7 per 100,000. Over this ten-year time frame, the highest relative increase observed among females was in those aged 60 and over (188.0%, from 0.2 to 0.7 per 100,000), though females in this age group exhibited the lowest rate of gonorrhea as compared to females in other age groups (data not shown). 
Discussion
Recent trends in the rates of reported cases of gonorrhea in Canada have shown overall increases, despite some year-to-year variation. The increases in rates since the late 1990s may be at least partly explained more sensitive testing methods and improved case finding (6).
Antimicrobial resistance may also play a significant role in the increase in reported rates of gonorrhea, as the proportion of isolates resistant to a number of antibiotics has increased over time, (7) which may lead to treatment failure and a longer duration of infectiousness in affected patients. Emerging antimicrobial resistance in gonorrhea has led to changes in treatment recommendations across Canada and elsewhere (8, 9, 10, 11) .
In 2012, the overall rates of reported cases of gonorrhea were substantially lower in Canada at 36.2 per 100,000 compared to the United States (107.5 per 100,000) (12), Australia (58.9 per 100,000) (13) and England (48.1 per 100,000) (14) . There was considerable variability in the differences observed across sexes; in Australia and England, gonorrhea rates were more than twice as high among males as compared to females, while the differences between sexes in Canada and the United States were less pronounced.
In conclusion, over a 10-year period, gonorrhea rates have increased almost 40% and these increases are particularly pronounced among young adults. While the reasons for these increases are likely multifactorial, it is possible that increasing gonococcal resistance to many available treatments has contributed to observed trends and should continue to be monitored. 
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Introduction
Syphilis has been nationally notifiable since 1924. It is caused by the bacterium Treponema pallidum and if left untreated, will progress through primary, secondary, latent and tertiary stages. Tertiary syphilis damages the central nervous system, cardiovascular system, eyes, skin and other internal organs (1). Individuals with early (symptomatic) syphilis infections are also at increased risk of contracting HIV and those co-infected with both pathogens are more likely to transmit HIV to their sexual partners (2) . In co-infected individuals, there is a greater chance of rapid progression to serious consequential conditions, such as neurosyphilis, often while those individuals are still infectious (3, 4, 5) . While all stages of syphilis are nationally notifiable, only primary, secondary and early latent syphilis (less than one year after the point of infection) are considered infectious and therefore are of major public health significance. As a result, only these stages are included in national reports.
From 1993 to 2001, rates of reported cases of infectious syphilis were very similar between males and females, with both sexes experiencing low rates (less than 1.0 per 100,000) over this time frame. In 2001, infectious syphilis rates began to climb sharply, particularly among males (6). 
Methods
Data collection
Data on laboratory-confirmed gonorrhea cases were reported to the Canadian Notifiable Disease Surveillance System (CNDSS) by provincial and territorial health authorities according to the Agency's Case Definitions for Communicable Diseases under National Surveillance (8) (see box below). Data are submitted in a variety of formats (e.g., line-listed electronic, paper-based case reports, or aggregate data) and are verified and loaded into the CNDSS database by Agency personnel.
Case definitions of infectious syphilis 1
Primary Syphilis -Laboratory confirmation of infection:
Identification of T. pallidum by dark-field microscopy, fluorescent antibody, nucleic acid testing or equivalent examination of material from a chancre or a regional lymph node,
OR
Presence of one or more typical lesions (chancres) and reactive treponemal serology, regardless of nontreponemal test reactivity, in individuals with no previous history of syphilis,
Presence of one or more typical lesions (chancres) and a fourfold or greater increase in the titre over the last known non-treponemal test in individuals with a past history of syphilis treatment.
Secondary Syphilis -Laboratory evidence of infection:
Identification of T. pallidum by dark-field microscopy, fluorescent antibody, nucleic acid testing or equivalent examination of mucocutaneous lesions, condylomata lata and reactive serology (non-treponemal and treponemal),
OR
Presence of typical signs or symptoms of secondary syphilis (e.g., mucocutaneous lesions, alopecia, loss of eyelashes and lateral third of eyebrows, iritis, generalized lymphadenopathy, fever, malaise or splenomegaly) AND Either a reactive serology (non-treponemal and treponemal OR a fourfold or greater increase in titre over the previous known non-treponemal test.
Early Latent Syphilis (< 1 year after infection) -Laboratory confirmation of infection:
An asymptomatic patient with reactive serology (treponemal and/or non-treponemal) who, within the previous 12 months, had one of the following: non-reactive serolog, symptoms suggestive of primary or secondary syphilis, exposure to a sexual partner with primary, secondary or early latent syphilis.
1 For the purpose of this summary, congenital syphilis and (non-infectious) late latent syphilis were not included.
Data analysis
Infectious syphilis data extracted from the CNDSS were analyzed by Centre for Communicable Diseases and Infection Control (CCDIC) staff. Rates were calculated by age group and sex using population estimates obtained from the Statistics Canada Demography Division. Rate change calculations were made on unrounded figures for greater precision.
Surveillance is considered to be within the mandate of federal/provincial/territorial (F/P/T) programs and does not constitute human research; therefore, no research ethics board approval was sought.
Results
In 2012, 2003 cases of infectious syphilis were reported, corresponding to a rate of 5.8 per 100,000 and a 101.0% increase from the 2003 rate of 2.9 per 100,000. The majority of cases (94.9%) reported in 2012 were among men. Between 2003 and 2012, rates among males increased by 128.3% from 4.8 to 11.0 per 100,000; conversely, rates among females decreased by 40.9% from 0.9 to 0.5 per 100,000 (Figure 1 ).
Figure 1: Overall and sex-specific rates of reported infectious syphilis, 2003 to 2012, Canada
As in previous years, in 2012, the majority (65.6%) of all reported cases of infectious syphilis were among men aged 30 years and older. The highest rates were among men aged 25 to 29 years, followed by men aged 20 to 24 years (21.5 and 21.2 per 100,000, respectively) ( Figure 2) . Among women, rates of reported cases of infectious syphilis were substantially lower; the highest rates among women were observed among those aged 20 to 24 years, followed by those aged 15 to 19 years (2.2 and 1.3 per 100,000, respectively).
Between 2003 and 2012, relative rate increases were observed in males of all age groups, with the exception of those in the 10 to 14 age group (where zero cases were reported). Over the same period, rates decreased among females of all ages, with the exception of those aged 10 to 14 (where zero cases were reported) and those in the 15 to 19 age group where rates increased from 1.2 to 1.3 per 100,000 (data not shown). 
Discussion
After a near-zero incidence of infectious syphilis, the number of reported cases began to rise in 2001 and continues to do so, especially among males. There is a significant difference in rates between males and females.
Rates have more than doubled in males in the last 10 years, whereas they have decreased by a little over 40% in females. This resurgence appears to be primarily due to transmission among men who have sex with men (MSM). Increasing sexually transmitted infection (STI) rates among MSM have also been observed in the United States and Europe. The causes for these increases are complex and include demographic shifts as well as changing sexual attitudes and social contexts related to risky sexual practices (9) .
There are several factors that must be taken into account when considering these data. For example, the number of cases of infectious syphilis in Canada is low relative to other STIs. As a result, population rates are variable and unstable and therefore changes over time should be interpreted with caution. That being said, the number of reported cases likely underestimates the true burden of infection; many people who are infected with syphilis do not have symptoms and therefore may not be tested by a health care practitioner.
Internationally, overall rates of infectious syphilis were lowest in the United States (5.0 per 100,000) (10), although this estimate does not include early latent cases. Among countries that included early latent syphilis cases, Australia had the highest rate (6.7 per 100,000) (11) and in England, the rate was 5.6 per 100,000 (12) compared to Canada's rate of 5.8 per 100,000. Variations in annual rates of infectious syphilis across countries should be interpreted with caution as a result of differing reporting practices.
In conclusion, over a 10-year period, Canada has witnessed a 40% decrease in syphilis rates in women and a 128% increase in syphilis rates in men, which is consistent with trends seen in other Western countries. The treatment and control of gonorrhea is complicated by the ability of N. gonorrhoeae to evolve and develop resistance to many of the antibiotics used to treat it (2, 3). The emergence of isolates with decreased susceptibilities to the cephalosporins (4, 5, 6, 7) and reports of treatment failures in Canada (8) and around the world raises the possibility of gonorrhea infections becoming untreatable in the future. The emergence of highlevel azithromycin resistant (≥256 mg/L) N. gonorrhoeae has been reported internationally (9) and isolates with this high level azithromycin resistance have now been identified in Canada.
Antimicrobial resistance to
The number of cultures available for antimicrobial susceptibility testing is on the decline due to the shift from the use of culture to Nucleic Acid Amplification Test (NAAT) for the diagnosis of gonorrhea. This is of concern as N. gonorrhoeae cultures are required for antimicrobial susceptibility testing and some jurisdictions in Canada no longer maintain the capacity to culture this organism. In fact, over 70% of gonococcal infections in Canada are now diagnosed using NAAT and therefore antimicrobial susceptibility data in these jurisdictions are not available. The National Microbiology Laboratory (NML), in collaboration with the provincial laboratories, has been monitoring the antimicrobial susceptibilities of N. gonorrhoeae since 1985. MICs were determined by agar dilution (11) and resistance was defined according to the Clinical and Laboratory Standards Institute (11) except for erythromycin (12) and azithromycin (13) . Decreased susceptibility breakpoints for ceftriaxone and cefixime were based on WHO definitions (14) . Gender and age data was available for 99.5% of the 2013 isolates tested at the NML. Of these, 83.1% were males ranging from 1 month to 74 years of age. A total of 16.9% of isolates were from females aged 2 to 71 years.
Third generation cephalosporins
In 2013, according to WHO definitions, 1.8% of isolates were identified as having decreased susceptibility to cefixime and 3.5% were identified as having decreased susceptibility to ceftriaxone. These rates are higher than they were in 2009 (1.2% decreased susceptibility to cefixime and 3.1% decreased susceptibility to ceftriaxone), but lower than in 2011 (4.2% decreased susceptibility to cefixime and 6.2% decreased susceptibility to ceftriaxone). In 2013, 3.9% of isolates were identified with decreased susceptibility to ceftriaxone and/or cefixime decreasing from 5.9% in 2012 and 7.6% in 2011. In 2012, seven isolates with combined decreased susceptibility to cephalosporins and resistance to azithromycin were identified (0.2%). In 2013, eight (0.3%) of these isolates were identified. These are the first isolates to emerge in Canada with both decreased susceptibility to cephalosporins and resistance to azithromycin thus threatening the success of currently recommended dual therapy treatment options.
Other antibiotics
The 
Discussion
The evolution of antimicrobial resistance in gonorrhea is complex and the emergence and spread of resistant isolates is a recognized global public health threat. Surveillance and monitoring of the antimicrobial susceptibilities of N. gonorrhoeae will continue to inform efforts to mitigate the impact of antimicrobial resistance in gonorrhea and guide therapeutic recommendations.
Reports of cefixime treatment failures and the observed MIC creep between 2001 and 2010 for both cefixime (from 0.016 mg/L to 0.125 mg/L) and ceftriaxone (from 0.016 mg/L to 0.063 mg/L) led to gonorrhea treatment changes. In 2011, the Canadian STI Guidelines issued updated recommendations for the use of combination gonorrhea therapy with 250 mg ceftriaxone intramuscularly and azithromycin 1 g orally as the first-line regimen in men-who-have-sex-with men (MSM) and in pharyngeal infections (15) .
Since the 2011 changes to gonorrhea treatment recommendations in Canada there has been a decrease in the proportion of isolates with elevated MICs to the cephalosporins. In 2011, 7.6% of isolates exhibited decreased susceptibility to ceftriaxone and/or cefixime according to the WHO definition. This decreased to 5.9% in 2012 and further declined to 3.9% of isolates tested in 2013.
Fortunately, dropping rates of reduced cefixime susceptibility are also being seen elsewhere. For example, the US reported declines to decreased cefixime susceptibility from 3.9% in 2010 to 2.9% in the first half of 2012 (16) . The UK reported the prevalence of isolates with decreased cefixime susceptibility dropped from 17.1% in 2010 to 10.8% in 2011 (17).
Enhancing surveillance to include linked epidemiological and laboratory data will assist with the limitations in the current passive surveillance system regarding data representativeness and interpretation. These improvements to the gonococcal surveillance program are expected with the Enhanced Surveillance of Antimicrobial Resistant Gonorrhea (ESAG) program beginning in 2014. 
